Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duelmen – page 118

1 729 clinical trials in Duelmen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duelmen at a glance
1 729
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 729 trials in Duelmen

Open in trial search

Lupus nephritis+1

Not recruiting

Study on Vemircopan for Adults with Lupus Nephritis or IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vemircopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Medica Scientia Innovation Research S.L.

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Huntington's disease

Not recruiting

Study on the Safety and Efficacy of Tominersen for Patients with Prodromal and Early Manifest Huntington's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tominersen
  • Sponsor:F. Hoffmann-La Roche AG

Uveal melanoma+2

Not recruiting

Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of BI 764198 for Patients with Focal Segmental Glomerulosclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Astellas Pharma Global Development Inc.

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Hyperphagia

Not recruiting

Study on Carbetocin Nasal Spray for Reducing Uncontrollable Hunger in Patients with Prader-Willi Syndrome

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carbetocin
  • Sponsor:Acadia Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duelmen

What the registry says about research in the country

01 Immune System Diseases

In Dülmen, several recruiting studies focus on immune system diseases, especially psoriasis and chronic spontaneous urticaria. The research is aimed at finding better ways to control symptoms, assess treatment benefit, and support longer-term disease management.

  • Moderate to severe plaque psoriasis
  • Mild to moderate psoriasis
  • Chronic spontaneous urticaria
  • Evaluating treatment effectiveness and safety

These trials include studies of new therapies and comparisons with established options to improve care for people living with persistent inflammatory skin conditions.

02 Skin and Connective Tissue Diseases

Research in skin and connective tissue diseases is a major part of the local clinical trial landscape, with studies covering atopic dermatitis, acne, and different forms of psoriasis. The overall goal is to test new topical and oral treatments that may offer better symptom relief and disease control.

  • Mild to moderate atopic dermatitis
  • Papulopustular acne
  • Chronic stable plaque psoriasis
  • Comparing new treatments with approved therapies or vehicle

These studies help researchers understand how well candidate treatments reduce skin inflammation, improve visible lesions, and support longer-lasting control of chronic skin disease.

03 Parasitic Diseases

Clinical research also includes parasitic diseases, with scabies being a key focus. The studies are designed to evaluate how well standard therapies work in clearing infection and restoring skin health.

  • Scabies
  • Assessing clinical response after treatment
  • Evaluating symptom resolution and treatment success

This area reflects practical, patient-centered research aimed at confirming effective care for a common contagious skin condition.

04 Topical Treatment Development

A number of trials in the city are centered on topical medicines for inflammatory skin disorders, including gels and ointments for acne, atopic dermatitis, and psoriasis. The focus is on comparing candidate products with approved treatments and non-active controls.

  • Testing new gels and ointments
  • Comparing against reference treatments
  • Improving local symptom control

These studies aim to refine everyday treatment options that may be easier to use and more effective for patients with chronic skin conditions.

05 Long-Term Disease Control

Some research is directed at long-term disease control, looking at how well treatments maintain benefit over time in chronic conditions such as psoriasis and urticaria. This helps determine whether a therapy can keep symptoms from returning or worsening.

  • Tracking time to disease worsening
  • Monitoring treatment durability
  • Supporting chronic disease management

Such studies are especially valuable for people who need sustained relief rather than short-term improvement alone.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.